A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy
- 4 February 2021
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 48 (4) , 465-477
Abstract
Intermittent androgen deprivation therapy with gonadotropin-releasing-hormone (GnRH) agonists can prevent or delay disease progression and development of castration resistant prostate cancer for subpopulations of prostate cancer patients. It may also reduce risk and severity of side effects associated with chemical castration in prostate cancer (PCa) patients. One of the earliest comprehensively documented clinical trials on this was reported in a Canadian patient population treated with leuprorelin preceded by a lead-in with cyproterone acetate. A systems-based mixed effect analysis of testosterone response in active and recovery phases allows inference of new information from this patient population. Efficacy of androgen deprivation therapy is presumed to depend on a treshold value for testosterone at the nadir, below which no additional beneficial effects on PSA reponse can be expected, and occurance of testosterone breakthroughs during active therapy. The present analysis results in a mixed effect model, incorporating GnRH receptor activation, testosterone turnover and feedback mechanisms, describing and predicting testosterone inhibition under intermittent androgen deprivation therapy on the individual and population level, during multiple years of therapy. Testosterone levels in these patients decline over time with an estimated first order rate constant of 0.083 year−1(T1/2 = 8.4 y), with a substantial distribution among this patient population, compared to the general population. PCa patients leaving the trial due to unmanageble PSA relapse appear to have slightly higher testosterone levels at the nadir than sustained responders. These findings are expected to contribute to an increased understanding of the role of testosterone in long term disease progression of prostate cancer.Keywords
This publication has 35 references indexed in Scilit:
- Pharmacokinetic/Pharmacodynamic Model of the Testosterone Effects of Triptorelin Administered in Sustained Release Formulations in Patients with Prostate CancerThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Androgen Deprivation Therapy in Advanced Prostate Cancer: Is Intermittent Therapy the New Standard of Care?Current Oncology, 2012
- Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?BJU International, 2012
- Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancerProstate Cancer and Prostatic Diseases, 2011
- Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapyBJU International, 2009
- Evaluation of drugs in pediatrics using K-PD models: perspectivesFundamental & Clinical Pharmacology, 2008
- International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta‐analysis of 1446 patientsBJU International, 2007
- Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate‐specific antigen recurrence after radiotherapyCancer, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancerCancer, 2006